Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Pharma
Argenx banks on Vyvgart prefilled syringe approval in 2025: exec
Simpler administration of argenx's FcRn inhibitor Vyvgart will form a key part of the immunology drugmaker's expansion plans moving forward.
Fraiser Kansteiner
Feb 19, 2025 1:36pm
Argenx sees early launch success for Vyvgart in CIDP
Nov 1, 2024 11:46am
Amgen's Uplizna posts strong results in myasthenia gravis trial
Sep 25, 2024 11:37am
Argenx's Vyvgart holds its own against AZ's rare disease duo
Jul 25, 2024 3:16pm
Argenx lays out bold ambitions for its chief drug Vyvgart
Jul 18, 2024 10:26am
Argenx gears up to launch Vyvgart in next potential indication
Apr 16, 2024 2:24pm
